Microscope view of cells and a worm, illustrating microbiology or biological research.
Illustration of a magnifying glass focusing on microorganisms, such as bacteria and viruses, with a detailed view of their shapes and structures.

The DEX-G2 Biomarker

Advancing Early Gastric Cancer Detection

Patients
Healthcare Professionals

A Breakthrough in Early Gastric Cancer Detection

Close-up of a woman with glasses and brown hair, wearing gloves, preparing a syringe with a liquid, likely for an injection or vaccination.

At Cizzle Bio, we are pushing the boundaries of cancer diagnostics with our innovative DEX-G2 gastric cancer blood test. Designed for early-stage detection of gastric cancer, this minimally invasive, highly accurate test harnesses cutting-edge biomarker technology to provide patients and clinicians with life-saving insights—often before symptoms appear.

PROBLEM

The Urgency of Early Detection

Gastric cancer remains one of the most lethal cancers globally, mainly due to late detection and limited screening options. Traditional diagnostic methods, such as endoscopy, are invasive, expensive, and often inaccessible. DEX-G2 addresses these challenges by offering a minimally invasive, cost-effective blood test that detects gastric cancer early, when treatment is most effective.¹

CHALLENGES
  • A doctor sits at a desk with his hand on his forehead, looking stressed or tired, in a bright medical office.

    LATE DETECTION

    Most gastric cancers are identified at advanced stages, reducing survival rates.²

  • Close-up of stethoscope resting on a medical bill showing patient service charges.

    LIMITED SCREENING ACCESS

    Costly and invasive procedures like endoscopy limit widespread screening.¹

  • Four people sitting on chairs in a waiting room, appearing to be in thought or prayer, with large windows behind them letting in natural light.

    UNDERSERVED POPULATIONS

    High-risk regions lack adequate screening due to factors like H. pylori and genetic predispositions.²

  • A worried elderly man sitting with his hand on his forehead, a female doctor talking to him, holding a clipboard, in a medical office.

    AWARENESS GAPS

    Routine gastric cancer screening is uncommon in the U.S. due to perceived lower risk.¹

SOLUTION

Dual-Action Biomarker Technology

DEX-G2

Illustration of a hand holding a petri dish with colored bacteria and microorganisms inside.
Illustration of various squiggly lines in pastel colors on a black background.

+

Cell-Free

miRNAs

Exosomal

miRNAs

The DEX-G2 test introduces a pioneering dual-biomarker strategy, combining:

This proprietary, AI-driven signature panel maximizes sensitivity while maintaining exceptional specificity, ensuring accurate detection of early-stage gastric cancer.

Exosomal miRNAs: Tumor-specific biomarkers, encapsulated in exosomes—tiny vesicles released by cancer cells—providing high specificity.

Cell-Free miRNAs: Highly sensitive indicators of general health abnormalities.

Proven Clinical Performance

0%

Specificity (Early Detection) 1

0%

Sensitivity (Early Detection) 1

0.00

AUC (Area Under Curve): 0.96, indicating outstanding diagnostic accuracy. 1

Clinical Validation

MULTICENTER STUDY

Validated through a rigorous multicenter clinical trial conducted across high-incidence regions including Japan and South Korea.¹

PATIENT COHORT

More than 800 patient specimens in training and validation cohorts.¹

How DEX-G2 Compares to Traditional Methods

Feature DEX-G2 Test Traditional Endoscopy
Procedure Simple blood draw Invasive, requires anesthesia
Accessibility Broad clinical integration Limited to specialized centers
Cost Cost-effective High cost for procedures
Turnaround Time Faster results Longer processing times
Patient Comfort Minimally invasive Can be uncomfortable/painful

Benefits of DEX-G2

A stylized map outline of the state of Texas with a shaded area in the southeastern region.

Patients

MINIMALLY INVASIVE

No anesthesia required—just a simple blood test.

EARLY DETECTION

Identifies gastric cancer before symptoms appear.

AFFORDABLE

Lower cost makes it accessible to more patients.

A colorful logo with interconnected blue, green, and yellow shapes forming a circular design.

Clinicians

FASTER DIAGNOSIS

Quick turnaround enables timely, more informed treatment decisions.

WORKFLOW INTEGRATION

Easily integrates as a pre-endoscopy screening tool.

REDUCES UNNECESSARY PROCEDURES

Helps avoid invasive methods.

A black background with a green upward-trending arrow and a blue arrow pointing upward, symbolizing growth or increase.

Healthcare Systems

SCALABLE

Designed for widespread screening.

COST SAVINGS

Cuts expensive diagnostic procedures.

BETTER OUTCOMES

Early detection leads to improved survival rates.

Pioneering Science. Global Partnerships.

Collaborative Innovation

Close-up portrait of a man wearing a dark suit and white shirt, smiling slightly, with short black hair and brown eyes.
Logo featuring three stylized human figures with outstretched arms inside a blue square, next to the text 'City of Hope'.

Professor and Chair, Molecular Diagnostics & Experimental Therapeutics
City of Hope Comprehensive Cancer Center

The DEX-G2 was developed from the pioneering research of renowned biomarker scientist Ajay Goel, Ph.D., AGAF, who currently serves as chair of the Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope Comprehensive Cancer Center. Dr. Goel’s groundbreaking hypothesis combined cell-free and exosomal miRNAs to create a new standard in precision diagnostics.

Key collaborators include:

  • Leading Asian cancer research institutions that contributed to the test’s clinical validation.

  • Partnerships with centers of excellence in cancer diagnostics.

Future Potential of DEX-G2 Technology

Expanding Beyond Gastric Cancer

Digital illustration of a stylized magnifying glass focusing on a DNA strand, with a background of glowing molecular structures.

Chronic Diseases

Other Cancers

Esophageal Cancer

Pancreatic Cancers

While DEX-G2 is currently focused on gastric cancer, its proprietary technology holds promise for:

  • Detecting other gastrointestinal cancers like pancreatic and esophageal cancer.

  • Expanding to broader liquid biopsy applications for various cancers and chronic diseases.

Saving Lives, One Test at a Time

At Cizzle Bio, our driving purpose—Detect Early. Save Lives.—inspires every breakthrough we deliver. By giving patients the power of early action and equipping physicians with precision diagnostics, we’re changing the course of cancer care and saving more lives.

A digital illustration of a DNA double helix structure with multiple Helix strands connected by horizontal bars, depicted in a light blue color on a white background with a pattern of similar DNA strands in the background. 
FOR PATIENTS
A nurse in blue scrubs smiling while showing a tablet to an elderly woman with white hair, who is also smiling. They are sitting on a bed in a bright room.

Take proactive steps—learn how to get tested.

Gastric Cancer Test 
FOR PHYSICIANS
Smiling African American female doctor in white coat with stethoscope, standing against plain light grey background.

Learn more about how to access our DEX-G2 biomarker tests.

Gastric Cancer Test

Join Us in Advancing Early Cancer Detection

Cizzle Bio is dedicated to providing innovative diagnostic solutions that save lives and improve quality of care. The DEX-G2 biomarker gastric cancer test is a critical step toward making early cancer detection accessible to all.

Together, we can detect earlier, treat sooner, and save more lives.

Stay updated on our advancements in technology, community impact, and industry leadership.

  • https://jamanetwork.com/journals/jamasurgery/fullarticle/2837074

  • National Cancer Institute. (n.d.). Stomach cancer survival rates and prognosis. U.S. Department of Health and Human Services. Retrieved October 30, 2025, from https://www.cancer.gov/types/stomach/survival

References: